NCT06583512Active, not recruiting
Treatment Duration of IPA
Invasive Pulmonary Aspergillosis Treatment Duration of Posaconazole-initiated Antifungal Strategy in Patients with Hematological Malignancies: a Prospective, Single-center Study
Source: ClinicalTrials.gov · Last updated 27 Dec 2024
Brief summary (registry, in English)
The goal of this observational study is to identify the duration of posaconazole-initiated antifungal treatment for IPA in patients with hematological malignancies and to explore the value of monitoring immune factors and cells in IPA treatment in order to assess practices in IPA management in Chinese hematology patients including tools to evaluate duration and discontinuation. The main question it aims to answer is: Does any indicators that could be used to guide the duration of IPA treatment? Does immune factors have value in monitoring IPA treatment? We will not do any interventions to participants. Participants will be monitored routinely for their clinical characteristics, microbiological test( including G/GM Test, Blood culture), Imaging examination, Blood routine, the number and function of immune cells, cytokines(IL-1β/IL-2/IL-4/IL-8/IL-10/IL-12/IL-17/IFN-α/IFN-γ/TNF-α)， and we will collect these datas for analysing.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 15 (estimated)
- First submitted
- 6 Aug 2024
- Start date
- 1 Dec 2024
- Primary completion date
- 31 Aug 2025
- Lead sponsor
- Peking University People's Hospital
- Diseases
- Childhood cancers
- NCT number
- NCT06583512
What you commit to
- Study type: Observational
- Planned participants: 15
- From 1 Dec 2024 to the primary completion date, 31 Aug 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Fungal or mycobacterial lung co infection at time of IPA diagnosis
- Hematological malignancy with lung location
Other
- Refuse to enroll
- Pregnancy or breastfeeding women
- Are expected to survive no more than 72 h
- Disseminated aspergillosis (lung and sinus aspergillosis can be included)
Who the study is looking for
- Informed consent form signed
- Patient with hematological malignancies
- Patients with posaconazole-initiated antifungal therapy
- Treatment duration ≥12w
Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Peking University People's Hospital Coordinator of this site? Confirm its status | Beijing | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.